Published: 16 July 2026
With this new definition, published in the journal The Lancet and presented at the European Society of Endocrinology (ESE) annual meeting, 56 medical societies worldwide underline the systemic nature of the condition.
170 Million Women Affected Worldwide
An estimated 170 million women suffer from PMOS. According to the World Health Organization (WHO), about one in eight women of reproductive age exhibits clinical symptoms. Alarmingly, around 70% of those affected remain undiagnosed.
The new name reflects the understanding that the cysts, which gave the syndrome its previous name, do not occur in all patients. Instead, metabolic warning signs are now emphasized. Experts recommend increased monitoring of blood sugar, HbA1c levels, insulin levels, and inflammatory markers.
Insulin Resistance as a Key Driver
Approximately 85% of women with PMOS exhibit insulin resistance. This condition makes body cells less responsive to insulin, contributing to chronic inflammation and significantly increasing the risk of type 2 diabetes.
In Germany, this finding correlates with the rising incidence of metabolic syndrome, affecting one in three individuals often without them realizing it. Overweight, high blood pressure, and elevated lipid levels lay the groundwork for future cardiovascular diseases.
Despite the serious implications, 70% of those affected remain undiagnosed, even though risk can be identified early through simple checks. In a free guide, you can find out about five metabolic warning signs and ways to monitor your blood sugar.
New Medications on the Horizon
The European Medicines Agency (EMA) has recommended an oral Semaglutide tablet as of May 22, 2026, with market approval expected by mid-August 2026. Concurrent studies on SGLT2 inhibitors and GLP-1 receptor agonists show promising side effects, potentially reducing Alzheimer’s risk by 43% and 33%, respectively.
Despite these advances, the German Society for Nutritional Medicine (DGEM) cautions against radical pharmacological treatments that could lead to muscle loss. A holistic approach that embraces lifestyle changes remains essential for effective management.
Focus on Sleep and Mental Health
Sleep disturbances and psychological stress are among the most common companions of PMOS. Recent fMRI studies reveal how sleep deprivation alters brain functionality, exacerbating anxiety. The guide provides actionable tips for improved sleep and emotional stability.
Research also highlights the neurological and psychological aspects of the condition. An fMRI study published in BMC Psychiatry indicates that sleep disorders can affect the brain’s default mode network, heightening anxiety and depression before menstruation.
Furthermore, the NAKO Health Study involving 150,000 participants suggests that metabolic risk factors can influence cognitive performance from a young age. To explore these connections specifically related to PMOS, the EASE study will begin at the University of Giessen in 2026, aiming to deepen our understanding of disease progression and optimize intervention strategies.
Disclaimer: No investment advice, no buy or sell recommendations. Information on prices, companies, and markets is subject to change without notice. Stock trading can lead to significant losses. Our articles may be partially or fully automated with AI support and reviewed.
de | science | 69776116 |
